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Abstract 
The oral S1PR1 agonist ponesimod demonstrated substantial efficacy in a phase II clinical trial of 
psoriasis.  Unfortunately, systemic side effects were observed, which included lymphopenia and 
transient bradycardia.  We sought to develop a topical soft-drug S1PR1 agonist with an improved 
therapeutic index.  By modifying ponesimod, we discovered an ester series of S1PR agonists.  To 
increase metabolic instability in plasma we synthesised esters described as specific substrates for 
paraoxonase and butyrylcholinesterases, esterases present in human plasma.   
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Psoriasis is a common chronic inflammatory skin disease that affects 2% of the population.1  52.3% 
of patients were dissatisfied with current treatments in a recent survey from the National Psoriasis 
Foundation in the US.1  Recently approved biological drugs targeting disease relevant receptors, such 
as secukinumab2 or ixekizumab3 for interleukin (IL)-17 and ustekinumab for IL-12/234 have brought 
great benefit to patients with severe symptoms of the disease.  However, a need remains for safe, 
convenient, efficacious therapies for mild and moderate psoriasis.  
Sphingosine-1-phosphate receptor (S1PR) agonists are of interest to the pharmaceutical industry, 
due to their potential to treat diseases of the immune system such as psoriasis and multiple sclerosis 
as well as cancer.5,6  S1PR agonists, such as fingolimod and ponesimod (Figure 1), initially activate 
sphingosine-1-phosphate receptors, but subsequently trigger receptor internalisation.  This shuts 
down the sphingosine 1-phosphate signalling pathway, which then prevents the maturation and 
migration of lymphocytes.7  In 2010 fingolimod was approved for the treatment of 
relapsing/remitting multiple sclerosis and is the only S1PR1 agonist approved to date.8   
  
In a phase 2 study in plaque psoriasis, a 40 mg oral dose of ponesimod, led to a 75% reduction in 
psoriasis area and severity index (PASI) score in 77% of the patients.9  This level of efficacy is 
competitive with other small molecules in development to treat psoriasis (apremilast10, tofacitinib11 
and sotrastaurin12).  Ponesimod was not however progressed into phase 3, possibly due to safety 
concerns.  Oral use of pan-S1PR and S1PR1 selective modulators is associated with several severe 
side effects such as lymphopenia, bradycardia and dyspnoea, which limits their utility as therapies 
for non-life threatening chronic diseases.5 
In mice, topical application of the S1PR agonist fingolimod led to a reduction in the number of 
Langerhans cells migrating to the lymph node.13  Work by Griffiths and co-workers has shown that 
Langerhans cell migration is higher in involved areas of patient’s skin than in non-involved areas of 
skin.14, 15  We hypothesised that local inhibition of Langerhans cell migration, through the effects of 
topical S1PR agonists, could restore a normal skin phenotype to patients with psoriasis. 
 
Figure 1. Selected S1PR1 modulators 
Due to the potential of S1PR agonists to act as efficacious therapies, for the treatment of psoriasis, 
we decided to embark on developing a topical S1PR1 modulator using a fast-follower approach, 
inspired by ponesimod.  Topical therapies apply drugs directly to the site of action and can lead to a 
reduction in the systemic exposure of a drug when compared to oral dosing.  However, due to the 
chronic nature of psoriasis and the need to be able to treat large body surface areas (>10%), there is 
a danger that topical application could lead to biologically relevant systemic drug concentrations.  To 
maximise the therapeutic index we decided to develop a soft drug.16, 17  Soft drugs are locally active, 
in this case in the skin, but then undergo rapid systemic metabolism, to metabolites, which are 
either inactive or rapidly cleared from the systemic circulation.18   
 
Esters can be metabolised in liver by esterases and cytochrome P450 enzymes.19  However, most 
tissues are capable of metabolising an ester.  Importantly, human blood contains a wide range of 
esterases and the rate of ester hydrolysis in blood can lead to ultra-rapid clearance,20 what we term 
a super-soft drug.  Because S1PR agonists induce transient bradycardia, and as blood returning to 
circulation from skin passes through the heart before reaching the liver, we felt that a very rapid 
blood clearance mechanism could potentially discharge the cardiotoxicity risk.  To select compounds 
which would be likely to demonstrate the desired pharmacokinetic profile, we targeted a human 
plasma stability half-life of <5 minutes.  We chose to first develop benzoate ester analogues of 
ponesimod to determine if they could demonstrate potential as super-soft drugs.  The desired 
compound would have S1PR pXC50 of >7 and a logP in the range of 2-4 which is believed to be 
optimal for skin penetration.21 
 
Compounds 4a and 5a-d were synthesised as shown in Scheme 1.  The (Z)-2-(propylimino)-3-(o-
tolyl)thiazolidin-4-one core 2 was synthesised utilising a one-pot, two step reaction.  Only the Z 
isomer was observed.  N-propylamine was reacted with 1-isothiocyanato-2-methylbenzene 1 to give 
the resulting thiourea, which was condensed with 2-bromoacetyl bromide followed by addition of 
pyridine to furnish the desired thiazolidin-4-one 2.  This core was then condensed with the 
appropriately substituted benzaldehyde 3a-b to furnish 4a and 5a.  Finally, esterification or 
  
amidation of 4a gave the desired products.  Based on the configurational analysis by X-ray, which 
characterised crystalline analogues of ponesimod as Z,Z22, all structurally related compounds 4a, 5a-
d, 11, 12a-f and 15a,b were assigned to the Z,Z-isomer.   
 
 
Scheme 1. Reagents and conditions for preparation of compounds 4a and 5a-d: (a) n-PrNH2 (1eq), 
CH2Cl2, rt (b) 2-bromoacetyl bromide (1eq) and pyridine (2eq), CH2Cl2, 0 ˚C to rt (two steps) (c) 
aldehyde (1eq), NaOAc (2eq), AcOH, 65 ˚C (d) alcohol (5eq), HOAt (1.5eq), EDC (1.5eq), DIPEA 
(2.5eq), CH2Cl2, rt. eq: equivalent; rt: room temperature; HOAt: 1-Hydroxy-7-azabenzotriazole; EDC: 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; DIPEA: N,N-Diisopropylethylamine. 
 
Table 1  
Effect of R2 substitution on S1PR1 activity, kinetic aqueous solubility and human plasma stability. 
 
Compound R1 R2 Kinetic 
solubility 
(µM)a 
CHI 
logDb 
S1PR1 
pIC50
c 
H Plasma 
Stability 
(half-life min)e 
Ponesimod - - 110 3.1 7.9 (0) >180 
5a Cl OMe 39 >4.4 8.6 (0.1) >180 
5b H OMe 28 >4.4 6.5 (0) >180 
4a H OH 163 1.0 <6 (0) - 
5c H OCH2CH2OH 110 3.4 6.9 (0) >180 
5d H NHCH2CH2OH >250 2.3 7.0 (0) >180 
a The aqueous solubility of the test compounds was measured using laser nephelometry. b Reverse-
phase HPLC method to determine the chromatographic hydrophobicity index (CHI). c All pIC50s 
reported in this table correspond to n of 2, reported as their geometric mean. The range of pIC50 
values is provided in brackets. d Incubated in human plasma at 37 ᵒC. 
 
We selected human plasma stability as a model for human blood metabolism.  Esters 5a-c and amide 
5d demonstrated half-lives of >180 minutes in human plasma, far greater than the <5 minutes we 
were aiming for.  S1PR1 activity was measured using a PathHunter β-Arrestin recruitment assay.23  
All of the ester and amide compounds in Table 1 were active and had pIC50 values ranging from 6.5 
to 7.0,  with the exception of compound 5a where a chlorine ortho to the ester provided 100-fold 
improvement in activity compared to 5b.  Gratifyingly, the parent carboxylic acid 4a, which is the 
  
desired metabolite of our esters/amides was less active, giving a pIC50 of <6 and meeting our 
targeted criteria for producing inactive metabolites. 
Aqueous solubility is an important parameter for topically applied drugs.  Increasing aqueous 
solubility, should directly increase skin penetration rates.24  Increasing aqueous solubility also 
increases the range of formulation options that can be used in pre-clinical development.  We were 
pleased to see that introduction of a hydrogen bond donor at R2 in 5c led to a 4-fold increase in 
solubility relative to 5b.  Changing the ester linker in 5c to an amide in 5d further improved solubility 
to >250 µM, probably due to improvements in lipophilicity (3.4 vs 2.3 respectively).   
Encouraged by the solubility and activity data, we focused our efforts on optimising the metabolic 
profile of the esters.  At this time, we identified that switching from the o-tolyl group used in 
ponesimod to an o-phenol 6 increased aqueous solubility 2-fold, presumably due to the reduction in 
lipophilicity (Figure 2).  As 6 was equipotent to ponesimod (pIC50 7.9) and to maximise compound 
solubility, subsequent compounds incorporated the o-phenol group.    
 
Figure 2. Improvements in aqueous kinetic solubility from introduction of o-phenol group 
Compounds 11, 12a-c, 15a and 15b were synthesised using the route shown in Scheme 2.  12a-c 
were more soluble than ponesimod, probably due to significant improvements in CHI logD (Table 2).  
As expected a clear trend can be seen between low lipophilicity and improved solubility.  
Homologation of the ester group (15a,b) showed increased lipophilicity (3.2 and 3.5 respectively) 
and a commensurate reduction in solubility.  However, as with 5a-d, amide 12a and esters 12b-c also 
showed a lack of metabolism in our human plasma stability assay (Table 2).   
  
 
Scheme 2. Reagents and conditions for preparation of compounds 11, 12a-f and 15a,b: (a) n-PrNH2   
(1eq), CH2Cl2, rt (b) 2-bromoacetyl bromide (1eq) and pyridine (2eq), CH2Cl2, 0 ˚C to rt (two steps) (c) 
aldehyde (1eq), NaOAc (2eq), AcOH, 85 ˚C (d) BBr3 (8eq), CH2Cl2, -78 ˚C to rt (e) For 12a-c. amine 
(3eq) or alcohol (5eq), HOAt (1.5eq), EDC (1.5eq), DIPEA (2.5 eq), CH2Cl2, rt (f) For 12d-f. alcohol, 
alkyl chloride or alkyl tosylate (1.1-1.5eq) K2CO3 (1.5eq), NaI (0.1eq), DMF, 70 ˚C (g) NEt3 (3eq), EDC 
(1.1eq), HOAt (1.1eq), alcohol (1.5eq) rt (h) BBr3 (5eq), CH2Cl2, -78 ˚C to rt. eq: equivalent; rt: room 
temperature; HOAt: 1-Hydroxy-7-azabenzotriazole; EDC: 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide; DIPEA: N,N-Diisopropylethylamine; DMF: dimethyl formamide. 
 
Table 2 
Effect of R1 substitution on kinetic aqueous solubility and human plasma stability. 
 
 
Compound n R1 Kinetic 
solubility 
(µM)a 
CHI logDb H Plasma 
Stability (half-
life min)c 
Ponesimod - - 110 3.1 >180 
12a 0 NHCH2CONMe2 219 1.9 >180 
12b 0 OCH2CH2CH2OH 183 2.3 >180 
12c 0 OCH2CH(±CH2OH)OH >250 1.8 >180 
  
15a 1 OMe 155 3.2 >180 
15b 2 OMe 79 3.5 >180 
a The aqueous solubility of the test compounds was measured using laser nephelometry. b Reverse-
phase HPLC method to determine the chromatographic hydrophobicity index (CHI). c Incubated in 
human plasma at 37 ᵒC. 
 
As simple esters had shown themselves to be stable to human plasma, we turned our attention to 
ester functional groups which had been shown to be unstable in human plasma in the literature 
(half-life <5mins).20  The most successful studies focused on optimising metabolism by the esterases 
paraoxonase25 and butyrylcholinesterases26, which are mainly expressed in blood plasma.      
We synthesised compounds 11 and 12d-f using the route shown in Scheme 2, which all contain ester 
groups that are unstable in human plasma when attached to other scaffolds.  Although 12d or 12e 
did not show sufficient clearance in human plasma we were pleased to identify compound 12f 
containing a (2-oxo-1,3-dioxolan-4-yl)methyl ester which is rapidly degraded in human plasma.  The 
half-life of this ester in human plasma was 9 minutes and metabolite identification confirmed the 
conversion to the inactive parent acid 11 (Figure 3).   
 
 
Figure 3. Profile of compound 12f being hydrolysed to 11 in human plasma. 12f was incubated in 
human plasma at 37 ᵒC. The experiment was conducted as an n of one to provide a qualitative 
analysis. 
Unfortunately 12f was also rapidly metabolised in human skin S9 fraction with a half-life of just 23 
minutes, far faster than the desirable half-life of >6h that we target for once daily dosing.  In fact, 
there are suggestions of a correlation between the relative stability of 12d-f in human plasma and 
skin S9 fraction.  It may be that the esterases responsible for the metabolism of 12f are present in 
both human plasma and skin S9 fraction or that skin and plasma esterases have similar substrate 
affinities.  Unfortunately, 12f was also inactive as a S1PR1 modulator.  
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Table 3 
Effect of R1 substitution on kinetic aqueous solubility and human plasma stability. 
 
Compound R1 H Plasma 
Stability (half-
life min)a 
Kinetic 
solubility 
(µM)b 
CHI 
logDc 
H Skin S9 
(half-life 
min)d 
S1PR1 
pIC50
e 
11 OH >180 - - - <6 (0) 
12d 
 
 
180 117 3.0 152 - 
12e 
 
 
61 79 2.8 40 - 
12f 
 
 
9 
 
79 3.3 23 <6 (0) 
a Incubated in human plasma at 37 ᵒC. b The aqueous solubility of the test compounds was measured 
using laser nephelometry. c Reverse-phase HPLC method to determine the chromatographic 
hydrophobicity index (CHI). d Stability measured in skin S9 over 180 mins in the presence of 
enzymatic cofactors. e All pIC50s reported in this table correspond to n of 2, reported as their 
geometric mean. The range of pIC50 values is provided in brackets.
 
 
In summary, using a fast follower approach, we identified a series of ester S1PR1 modulators.  
Further optimisation led to improved solubility and identification of ester 12d that is plasma 
unstable.  Unfortunately, the ester is inactive and is metabolised in human skin models.  Further 
efforts will focus on identifying an active, skin stable compound that is rapidly metabolised 
systemically will be disclosed in due course.   
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